References

1. Aberg JA, Price RW, Heeren DM, Bredt B. A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with AIDS, following immunologic response to antiretroviral therapy. J Infect Dis 2002, 185:1179-82. http://amedeo.com/lit.php?id=11930330

2. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004, 363:1764-7. http://amedeo.com/lit.php?id=15172774

3. Chariyalertsak S, Supparatpinyo K, Sirisanthana T, et al. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced HIV infection in Thailand. Clin Infect Dis 2002, 34:277-84. http://amedeo.com/lit.php?id=11740718

4. Hamill RJ, Sobel J, El-Sadr W, et al. Randomized double blind trial of Ambisome and amphotericin B in acute cryptococcal meningitis in AIDS patients. 39th ICAAC 1999, San Francisco; Abstract 1161

5. Kirk O, Reiss P, Uberti-Foppa C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002, 137:239-50. http://amedeo.com/lit.php?id=12186514

6. Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997, 11:1463-71. http://amedeo.com/lit.php?id=9342068

7. Manfredi R, Pieri F, Pileri SA, Chiodo F. The changing face of AIDS-related opportunism: cryptococcosis in the HAART era. Case reports and Literature review. Mycopathologia 1999, 148:73-8. http://amedeo.com/lit.php?id=11189746

8. McKinsey DS, Wheat LJ, Cloud GA, Itraconazole prophylaxis for fungal infections in patients with advanced HIV infection: randomized, placebo-controlled, double-blind study. Clin Infect Dis 1999, 28:1049-56. http://amedeo.com/lit.php?id=10452633

9. Mussini C, Pezzotti P, Miro JM, et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis 2004, 38:565-71.http://amedeo.com/lit.php?id=14765351

10. Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999, 28:291-6. http://amedeo.com/lit.php?id=10064246

11. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000, 30:710-8. http://amedeo.com/lit.php?id=10770733

12. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the AIDS. N Engl J Med 1997, 337:15-21. http://amedeo.com/lit.php?id=9203426

13. Vibhagool A, Sungkanuparph S, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowon-watanuwong C, Ingsathit A. Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis 2003, 36:1329-31. http://amedeo.com/lit.php?id=12746781

14. Weitzel A, Arasteh K, Mertensk├Âtter T, et al. Kryptokokkosen bei HIV-positiven Patienten in Deutschland - eine Auswertung 24 deutscher Zentren. In: Brockmeyer NH et al. HIV-Infekt, SpringerVerlag; 1999.

Was this article helpful?

0 0

Post a comment